RxDoctor Payments Data

Hassan Tahir, MD

Interventional Cardiology · Cincinnati, OHNPI 1164830824

Payments from drug & device makers

$3,078in general payments, 2019–2025

Across 172 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$615
  • Novartis$403
  • AstraZeneca$320
  • Abbott$297
  • Boston Scientific$222
  • Merck$216
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,01398%
  • Education$652%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,078 in reported general payments places this provider in the 35th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$113,722
Medicare patients
1,248
Services billed
2,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$122,048
EntrestoSacubitril/Valsartan79$76,720
XareltoRivaroxaban46$38,982
BrilintaTicagrelor40$31,478
FarxigaDapagliflozin Propanediol26$24,550
Midodrine Hcl22$2,259
Prasugrel Hcl25$2,195
Bisoprolol Fumarate100$1,462
Metoprolol Succinate162$1,350
Rosuvastatin Calcium92$834
Amiodarone Hcl28$765
Atorvastatin Calcium93$607
Losartan Potassium129$544
ClopidogrelClopidogrel Bisulfate64$511
Spironolactone60$493

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$200$122,04896 claims
NovartisEntresto$403$76,72079 claims
AstraZenecaBrilinta, Farxiga$320$56,02866 claims
Johnson & JohnsonXarelto$199$38,98246 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 256 interventional cardiology providers in Ohio.

Other interventional cardiology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →